Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 10/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394823 | 0.90 | FSHR (0.65) | FSHRKDR | |
| SCHEMBL3425195 | 0.88 | FSHR (0.58) | FSHRHTR2AEPHX2KDRHTR2C | |
| SCHEMBL3397813 | 0.88 | FSHR (0.54) | FSHRHTR2AKCNH2KDR | |
| SCHEMBL3393357 | 0.87 | FSHR (0.56) | FSHRKDR | |
| SCHEMBL3396056 | 0.86 | FSHR (0.55) | FSHRKDR | |
| SCHEMBL3398201 | 0.86 | FSHR (0.59) | FSHRKDR | |
| SCHEMBL3396766 | 0.85 | FSHR (0.58) | FSHRKDR | |
| SCHEMBL4600077 | 0.84 | FSHR (0.54) | FSHRHTR2AKCNH2KDR | |
| SCHEMBL3394638 | 0.84 | FSHR (0.53) | FSHRKDRMAPK14 | |
| SCHEMBL4601614 | 0.83 | FSHR (0.56) | FSHRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674909-B2 | Biphenyl-4-carboxylic acid {1-acetyl-4-[4-(2-dimethylammo-ethoxy-phenyl]-2,2,4-trimethyl-1,2,3,4-tetrahydro-quinolin-6-yl}-amide; fertility regulation; follicle stimulating hormone (FSH) | N.V. ORGANON (NL) | 2010-03-09 | — | — | US | disclosed |
| EP-1578727-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS FSH RECEPTOR MODULATORS | ORGANON NV (NL) | 2008-04-16 | — | — | EP | disclosed |
| US-20060167047-A1 | Tetrahydorquinoline derivatives and their use as fsh receptor modulators | MERCK SHARP & DOHME B.V. (NL) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167047-A1 | Tetrahydorquinoline derivatives and their use as fsh receptor modulators | FSHR, GNRHR, LHCGR | FSHR 1/4885HTR2A 102/4885KCNH2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.